FULCRUM THERAPEUTICS, INC. Deferred Tax Assets, Deferred Income
FULCRUM THERAPEUTICS, INC. (FULC) had Deferred Tax Assets, Deferred Income of $251.00 thousand as of 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Notes › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2024-02-27
- 2023-12-31: Deferred Tax Assets, Deferred Income $251.00K.
- 2022-12-31: Deferred Tax Assets, Deferred Income $0.00; Deferred Tax Assets, Deferred Income as first filed $251.00K.
- 2021-12-31: Deferred Tax Assets, Deferred Income $1.06M.
- 2020-12-31: Deferred Tax Assets, Deferred Income $1.79M.
| Period end | Deferred Tax Assets, Deferred Income | Deferred Tax Assets, Deferred Income as first filed |
|---|---|---|
| 2023-12-31 | $251.00K 10-K · filed 2024-02-27 | |
| 2022-12-31 | $0.00 10-K · filed 2024-02-27 | $251.00K 10-K · filed 2023-03-09 |
| 2021-12-31 | $1.06M 10-K/A · filed 2023-06-26 | |
| 2020-12-31 | $1.79M 10-K/A · filed 2023-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |